---
figid: PMC7884707__41392_2020_430_Fig4_HTML
figtitle: Wnt/Beta-Catenin signaling pathway-mediated therapy resistance in CSCs
organisms:
- Homo sapiens
- Mus musculus
- Drosophila melanogaster
- NA
organisms_ner:
- Mus musculus
- Homo sapiens
- Drosophila melanogaster
- Danio rerio
pmcid: PMC7884707
filename: 41392_2020_430_Fig4_HTML.jpg
figlink: pmc/articles/PMC7884707/figure/Fig4/
number: F4
caption: Wnt/β-Catenin signaling pathway-mediated therapy resistance in CSCs. In the
  absence of Wnt signaling, β-catenin is bound to the Axin complex, which contains
  APC and GSK3β and is, phosphorylated, leading to ubiquitination and proteasomal
  degradation through the β-Trcp pathway. In the presence of Wnt signaling, the binding
  of LRP5/6 and FZD inhibits the activity of the Axin complex and the phosphorylation
  of β-catenin, allowing β-catenin to enter the nucleus, and then bind to TEF/TCF
  to form a complex, which then recruits cofactors to initiate downstream gene expression.
  Several proteins (CDH1, SMOC2, SOX8, PAF, PTK2, CD44 and ID1) along with miR-708-5p
  regulate Sorafenib resistance, Differential therapy resistance, Cisplatin resistance,
  Paclitaxel resistance and Castration resistance
papertitle: 'Targeting cancer stem cells for reversing therapy resistance: mechanism,
  signaling, and prospective agents.'
reftext: He-Ming Zhou, et al. Signal Transduct Target Ther. 2021;6:62.
year: '2021'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9114478
figid_alias: PMC7884707__F4
figtype: Figure
redirect_from: /figures/PMC7884707__F4
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7884707__41392_2020_430_Fig4_HTML.html
  '@type': Dataset
  description: Wnt/β-Catenin signaling pathway-mediated therapy resistance in CSCs.
    In the absence of Wnt signaling, β-catenin is bound to the Axin complex, which
    contains APC and GSK3β and is, phosphorylated, leading to ubiquitination and proteasomal
    degradation through the β-Trcp pathway. In the presence of Wnt signaling, the
    binding of LRP5/6 and FZD inhibits the activity of the Axin complex and the phosphorylation
    of β-catenin, allowing β-catenin to enter the nucleus, and then bind to TEF/TCF
    to form a complex, which then recruits cofactors to initiate downstream gene expression.
    Several proteins (CDH1, SMOC2, SOX8, PAF, PTK2, CD44 and ID1) along with miR-708-5p
    regulate Sorafenib resistance, Differential therapy resistance, Cisplatin resistance,
    Paclitaxel resistance and Castration resistance
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Ctnnb1
  - Smoc2
  - Dvl1
  - Cdh1
  - Fzr1
  - Mark2
  - Apc
  - Axin1
  - Gsk3b
  - Cd44
  - Ptk2
  - Id1
  - Idh1
  - Sox8
  - Ep300
  - Bcl9
  - Paf
  - Pclaf
  - Crebbp
  - Pag1
  - Cytip
  - Lrp6
  - Lrp5
  - FZD1
  - FZD10
  - FZD2
  - FZD3
  - FZD4
  - FZD5
  - FZD6
  - FZD7
  - FZD8
  - FZD9
  - CTNNB1
  - SMOC2
  - DVL1
  - DVL1P1
  - DVL2
  - DVL3
  - IFT81
  - CDH1
  - FZR1
  - MARK2
  - APC
  - PROC
  - AXIN1
  - AXIN2
  - GSK3B
  - CD44
  - PTK2
  - ID1
  - SOX8
  - EP300
  - BCL9
  - PCLAF
  - CREBBP
  - EIF4E
  - OPN1LW
  - PAG1
  - PCBP4
  - HNF4A
  - LRP6
  - LRP5
  - fz
  - arm
  - dsh
  - nkd
  - fzr
  - Apc2
  - Axn
  - Fs(3)Apc
  - sgg
  - gskt
  - Fak
  - osa
  - nej
  - lgs
  - atms
  - pygo
  - CBP
  - eIF4E1
  - pan
  - arr
  - ctnnb1
  - smoc2
  - cdh1
  - si:busm1-180o5.1
  - si:busm1-180o5.2
  - mark2b
  - apc
  - gsk3ba
  - cd4-1
  - ptk2ab
  - id1
  - sox8b
  - bcl9
  - elk4
  - lrp6
  - lrp5
  - Sorafenib
  - Cisplatin
  - Paclitaxel
---
